JP2019512233A - 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 - Google Patents

凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 Download PDF

Info

Publication number
JP2019512233A
JP2019512233A JP2018547409A JP2018547409A JP2019512233A JP 2019512233 A JP2019512233 A JP 2019512233A JP 2018547409 A JP2018547409 A JP 2018547409A JP 2018547409 A JP2018547409 A JP 2018547409A JP 2019512233 A JP2019512233 A JP 2019512233A
Authority
JP
Japan
Prior art keywords
protein
dna
expression vector
seq
diphtheria toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018547409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019512233A5 (https=
Inventor
ウィリアム アール． ビシャイ
ウィリアム アール． ビシャイ
ジョン アール． マーフィー
ジョン アール． マーフィー
ローレン チャン
ローレン チャン
シャシャンク グプタ
シャシャンク グプタ
シンシア ケイ． バーレン
シンシア ケイ． バーレン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Original Assignee
Boston University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University filed Critical Boston University
Publication of JP2019512233A publication Critical patent/JP2019512233A/ja
Publication of JP2019512233A5 publication Critical patent/JP2019512233A5/ja
Priority to JP2022177061A priority Critical patent/JP7532475B2/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/77—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Corynebacterium; for Brevibacterium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018547409A 2016-03-10 2017-03-10 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法 Pending JP2019512233A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022177061A JP7532475B2 (ja) 2016-03-10 2022-11-04 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662306281P 2016-03-10 2016-03-10
US62/306,281 2016-03-10
PCT/US2017/021715 WO2017156356A1 (en) 2016-03-10 2017-03-10 Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022177061A Division JP7532475B2 (ja) 2016-03-10 2022-11-04 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Publications (2)

Publication Number Publication Date
JP2019512233A true JP2019512233A (ja) 2019-05-16
JP2019512233A5 JP2019512233A5 (https=) 2020-02-27

Family

ID=59789900

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018547409A Pending JP2019512233A (ja) 2016-03-10 2017-03-10 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
JP2022177061A Active JP7532475B2 (ja) 2016-03-10 2022-11-04 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022177061A Active JP7532475B2 (ja) 2016-03-10 2022-11-04 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法

Country Status (12)

Country Link
US (1) US10988512B2 (https=)
EP (1) EP3426785A4 (https=)
JP (2) JP2019512233A (https=)
KR (1) KR102430891B1 (https=)
CN (2) CN118599011A (https=)
AU (1) AU2017230792B2 (https=)
BR (1) BR112018068055A2 (https=)
CA (1) CA3017143A1 (https=)
IL (2) IL261660A (https=)
MX (1) MX2018010850A (https=)
WO (2) WO2017156356A1 (https=)
ZA (1) ZA201806450B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538898A (ja) * 2019-07-01 2022-09-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EP3762401A4 (en) * 2018-03-06 2021-12-08 The Johns Hopkins University CANCER TREATMENT OR PREVENTION METHODS USING TREG DEPLETING AGENT AND CHECKPOINT INHIBITOR
BR112021023345A2 (pt) 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
EP3845556A1 (fr) * 2019-12-31 2021-07-07 Peptinov SAS Conjugue immunogene destine a induire une reponse immunitaire dirigee contre l interleukine-6
EP4107187A4 (en) 2020-02-21 2024-07-03 Pandion Operations, Inc. TISSUE-TARGETED IMMUNOTOLERANCE WITH A CD39 EFFECTOR
KR20230102682A (ko) * 2021-12-30 2023-07-07 (주)셀트리온 목적 단백질의 발현 방법
CN114903896B (zh) * 2022-05-30 2023-07-25 广西大学 贝达喹啉在制备治疗弓形虫病药物中的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60227681A (ja) * 1983-07-29 1985-11-12 グル−プマン・ドウ・ジエニ・ジエネテイツク（ジエー・３） ジフテリア毒素のシグナルペプチドをコ−ドするヌクレオチド配列、このヌクレオチド配列を含有するベクタ−、これらによる微生物の形質転換およびこうして得られるペプチド組成物
JPH03504248A (ja) * 1988-05-19 1991-09-19 ザ・ベス・イスラエル・ホスピタル・アソシエーション 外来抗原に対する寛容の誘発
JP2014518061A (ja) * 2011-06-01 2014-07-28 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質
US8865866B2 (en) * 2003-11-25 2014-10-21 Anjin Group, Inc. Diphtheria toxin variant

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
US5707644A (en) 1989-11-04 1998-01-13 Danbiosyst Uk Limited Small particle compositions for intranasal drug delivery
WO1991013090A1 (en) 1990-03-02 1991-09-05 Diane Williams Improved chimeric toxins
US5466468A (en) 1990-04-03 1995-11-14 Ciba-Geigy Corporation Parenterally administrable liposome formulation comprising synthetic lipids
NO175188C (no) * 1990-06-27 1994-09-14 Sjur Olsnes Fremgangsmåte for fremstilling av et peptidkonjugat med evne til å trenge inn i cellecytosol
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US5756353A (en) 1991-12-17 1998-05-26 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol-and liposome-based delivery
ES2105262T3 (es) 1992-05-18 1997-10-16 Minnesota Mining & Mfg Dispositivo de suministro de farmaco a traves de las mucosas.
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5654273A (en) 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US6737514B1 (en) 1998-12-22 2004-05-18 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6613308B2 (en) 2000-09-19 2003-09-02 Advanced Inhalation Research, Inc. Pulmonary delivery in treating disorders of the central nervous system
WO2004007663A2 (en) 2002-05-22 2004-01-22 Advanced Microbial Solutions Corporation Gene expression using metal ion dependent repressor/operator tandems
AU2006260240B2 (en) * 2005-06-21 2012-03-15 The Research Foundation For Microbial Diseases Of Osaka University Therapeutic agent for cancer
AU2008279550B2 (en) 2007-06-21 2012-08-09 Angelica Therapeutics, Inc. Modified toxins
EP2600843B9 (en) * 2010-07-19 2020-03-11 Pressure BioSciences, Inc. Therapeutic protein compositions having reduced immunogenicity and/or improved efficacy
WO2012039954A2 (en) * 2010-09-08 2012-03-29 The Scripps Research Institute Reliable stabilization of n-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns
WO2012110596A1 (en) * 2011-02-16 2012-08-23 Friedrich-Alexander-Universität Erlangen-Nürnberg Fusion protein for the treatment of immunologic or allergic reactions
US8906681B2 (en) * 2011-08-02 2014-12-09 The Scripps Research Institute Reliable stabilization of N-linked polypeptide native states with enhanced aromatic sequons located in polypeptide tight turns

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60227681A (ja) * 1983-07-29 1985-11-12 グル−プマン・ドウ・ジエニ・ジエネテイツク（ジエー・３） ジフテリア毒素のシグナルペプチドをコ−ドするヌクレオチド配列、このヌクレオチド配列を含有するベクタ−、これらによる微生物の形質転換およびこうして得られるペプチド組成物
JPH03504248A (ja) * 1988-05-19 1991-09-19 ザ・ベス・イスラエル・ホスピタル・アソシエーション 外来抗原に対する寛容の誘発
US8865866B2 (en) * 2003-11-25 2014-10-21 Anjin Group, Inc. Diphtheria toxin variant
JP2014518061A (ja) * 2011-06-01 2014-07-28 シャモン ユニヴァーシティー ジフテリア毒素の無毒性突然変異体ｃｒｍ１９７又はその断片を含む融合タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"FUSION PROTEIN [SYNTHETIC CONSTRUC]" [23-JUL-1993] RETRIEVED FROM GENBANK [ONLINE] ACCESSION NO.AAA, JPN6020047981, ISSN: 0004817446 *
PROC. NATL. ACAD. SCI., 1994, VOL. 91, PP. 9646-9650, JPN6020047980, ISSN: 0004817445 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022538898A (ja) * 2019-07-01 2022-09-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
JP7704690B2 (ja) 2019-07-01 2025-07-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗癌化合物ｅ７７６６の治療コンプライアンスを向上させるシステム
US12564600B2 (en) 2019-07-01 2026-03-03 Eisai R&D Management Co., Ltd. System for enhancing therapeutic compliance of the anti-cancer compound E7766

Also Published As

Publication number Publication date
CN109790545A (zh) 2019-05-21
WO2017156356A1 (en) 2017-09-14
CA3017143A1 (en) 2017-09-14
US20190071472A1 (en) 2019-03-07
CN118599011A (zh) 2024-09-06
KR102430891B1 (ko) 2022-08-09
ZA201806450B (en) 2020-12-23
IL291586A (en) 2022-05-01
EP3426785A1 (en) 2019-01-16
MX2018010850A (es) 2019-05-15
AU2017230792A1 (en) 2018-10-18
WO2018164712A1 (en) 2018-09-13
EP3426785A4 (en) 2019-12-25
AU2017230792A8 (en) 2018-11-29
IL261660A (en) 2018-10-31
JP2023011857A (ja) 2023-01-24
BR112018068055A2 (pt) 2019-01-08
AU2017230792B2 (en) 2023-08-10
KR20190016934A (ko) 2019-02-19
US10988512B2 (en) 2021-04-27
JP7532475B2 (ja) 2024-08-13

Similar Documents

Publication Publication Date Title
JP7532475B2 (ja) 凝集体を含まない単量体のジフテリア毒素融合タンパク質の生成方法及び治療的使用法
US8445650B2 (en) Mutant botulinum neurotoxin serotype A polypeptide and uses thereof
CN101484469B (zh) 生产胰岛素样生长因子-ⅰ的方法
KR102862473B1 (ko) 인간 키누레니나제 효소 및 이의 사용법
JP5097544B2 (ja) 炭疽菌からの防御抗原の調製
JP2019520392A (ja) ヒト酵素媒介性シスチン枯渇
US12186376B2 (en) Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
JP2002505083A (ja) 組換え脂質化ＰｓａＡタンパク質、調製法および使用
EP3622066A1 (en) Human-enzyme mediated depletion of homocysteine for treating patients with hyperhomocysteinemia and homocystinuria
EP0948624B1 (en) Mutants of streptococcal toxin a and methods of use
US11965009B2 (en) Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
US11203626B2 (en) Methods of producing aggregate-free monomeric diphtheria toxin fusion proteins and therapeutic uses
EP1108038A1 (en) Superoxide dismutase as a vaccine antigen
CN107176976A (zh) 微小rna31前体编码多肽在制备免疫调节药物中的应用
JP2025517661A (ja) 切断型インターロイキン３３とインターロイキン２とを含む組成物
CN1211924A (zh) 抗卷旋杆菌的菌苗复合物
WO2012126150A1 (zh) 具有镇痛活性的肽及其制备方法
HK40003962A (zh) 用於治疗胱氨酸尿症患者的人类酶介导的胱氨酸剔除

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20201211

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220705